Tumor-specific expression of CYP2W1 has been suggested as an attractive target for CRC therapy exploiting either its ability to activate certain prodrugs to cytotoxic metabolites or using CYP2W1 as a new tumor-associated antigen for immunotherapy-based treatment. This evidence concerns the gene CYP2W1 and colorectal carcinoma.